natgillin/translations-raw huggingface dataset:
In factor VII deficiency, the dose is 15 to 30 micrograms/kg every four to six hours until the bleeding is controlled.
Pri pomanjkanju faktorja VII je odmerek 15 do 30 mikrogramov na kilogram telesne mase vsakih 4 do 6 ur, dokler se ne vzpostavi nadzor nad krvavitvijo.
In faeces, bosutinib and N-desmethyl bosutinib were the major drug-related components.
V blatu sta bila bosutinib in N-demetiliran bosutinib najpomembnejši z zdravilom povezani sestavini.
In families with one flu patient, 7% of the family members in the household developed flu when receiving Tamiflu, compared with 20% of those receiving no preventative treatment.
V družinah z enim članom, obolelim za gripo, je 7 % družinskih članov v gospodinjstvu zbolelo za gripo ob prejemanju zdravila Tamiflu v primerjavi z 20 % obolelih, ki niso prejemali nobenega preventivnega zdravljenja.
In feces, approximately 15% of the dose was excreted as parent drug.
V blatu se je približno 15 % odmerka izločilo kot matično zdravilo.
In feces, approximately 15% of the dose was excreted as parent drug.
V blatu se je približno 15 % odmerka izločilo kot nespremenjenega.
In feed inclusion rate
Razmerja vsebnosti v krmi
In female adult patients with metastatic breast cancer, subcutaneous co-administration of 40,000 IU/ml epoetin alfa with trastuzumab 6 mg/kg had no effect on the pharmacokinetics of trastuzumab.
Pri odraslih bolnicah z metastatskim rakom dojke ni imelo subkutano sočasno dajanje 40.000 i.e./ml epoetina alfa s trastuzumabom 6 mg/kg nobenega učinka na farmakokinetiko trastuzumaba.
In female mice an increased incidence, dose-dependent, of bronchiolo-alveolaradenomas and carcinomas of the lung was noted.
Pri mišjih samicah je bilo ugotovljeno od odmerka odvisno zvečanje pogostnosti bronhioloalveolarnih adenomov in karcinomov pljuč.
In female mice, atazanavir exposure at a dose that produced single-cell necrosis was 12 times the exposure in humans given 400 mg once daily.
Pri mišjih samicah je bila izpostavljenost atazanavirju ob odmerku, ki je povzročil nekrozo posameznih jetrnih celic, 12-krat tolikšna kot je izpostavljenost pri človeku ob uporabi 400 mg enkrat na dan.
In female pups of the mid and high dose groups of 30 mg Fe/kg/day and 60 mg Fe/kg/day respectively (HED of 4.8 mg Fe/kg/day and
Pri podganjih samičkah skupine s srednje velikimi – 30 mg Fe/kg/dan in velikimi odmerki 60 mg Fe/kg/dan (kar ustreza odmerku 4,8 mg Fe/kg/dan oz.
In females administered mirabegron at the 50 mg dose, the mean difference from placebo on QTcI interval at 5 hours post dose was 3.67 msec (upper bound of the one-sided 95% CI 5.72 msec).
Pri ţenskah, ki so prejele odmerek 50 mg mirabegrona, je bila povprečna razlika intervala QTcI v primerjavi s placebom po 5 urah 3,67 milisekund (zgornja meja enostranskega 95 % IZ
In females of childbearing potential, Ribavirin must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
Pri ženskah v rodni dobi zdravljenja z zdravilom Ribavirin Teva ne smete uvesti, dokler ne dobite negativnega izvida testa nosečnosti tik pred začetkom zdravljenja
In females of childbearing potential, Ribavirin Mylan must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
Pri ženskah v rodnem obdobju zdravljenja z zdravilom Ribavirin Mylan ne smete uvesti, dokler ne dobite negativnega izvida testa nosečnosti tik pred začetkom zdravljenja;
In females Ovarian Hyperstimulation Syndrome (OHSS)
Pri ženskah Sindrom hiperstimulacije jajčnikov (Ovarian Hyperstimulation Syndrome - OHSS)
In females, this increased incidence was noted after the first year of treatment and persisted during long-term treatment.
Pri ženskah so to večjo pojavnost opazili po prvem letu zdravljenja, ohranila pa se je tudi med dolgotrajnim zdravljenjem in je med dolgotrajnim zdravljenjem.
In females, this increased incidence was noted after the first year of treatment and persisted during long-term treatment.
Pri ženskah so večjo pojavnost opazili po prvem letu zdravljenja ohranila pa se je tudi med dolgotrajnim zdravljenjem.
In females, this increased incidence was noted after the first year of treatment and persisted during long-term treatment.
Pri ženskah so večjo pojavnost opazili po prvem letu zdravljenja, ohranila pa se je tudi med dolgotrajnim zdravljenjem.
In Fendrix, it is used with an ‘adjuvant system’ which contains ‘MPL’, a purified fat from bacteria, and an aluminium compound.
V cepivu Fendrix se uporablja s „sistemom adjuvansov”, ki vsebuje „MPL”, prečiščeno maščobo iz bakterij in aluminijevo spojino.
In ferrets: Transient moderate swelling, pruritus and erythema at the implant site.
Pri belih dihurjih: Na mestu implantata je mogoče opaziti prehodno zmerno oteklino, srbenje in pordelost.
In fertility studies in both male and female rats, abiraterone acetate reduced fertility, which was completely reversible in 4 to 16 weeks after abiraterone acetate was stopped.
V študijah plodnosti pri samicah in samcih podgan je abirateronacetat zmanjšal plodnost, ki pa je po 4 do 16 tednih po ukinitvi izzvenela.
In fertility studies in male and female rats, no effects on sperm count, motility and viability, or on mating performance or fertility were observed at exposures that were 21 and 43 times the expected therapeutic level in humans, respectively; nor was there any adverse effect on the development of the pre-implantation embryo or on implantation.
V študijah plodnosti na podganjih samcih in samicah niso opazili nobenih učinkov na število, gibljivost in preživetje spermijev ali na uspešnost parjenja ali plodnost pri izpostavljenostih, ki so bile 21-krat in 43-krat višje od pričakovane terapevtske ravni pri ljudeh, niti ni bilo nobenega neželenega učinka na razvoj zarodka pred ugnezditvijo ali na ugnezditev samo.
In fertility studies in male and female rats, no effects on sperm count, motility and viability, or on mating performance or fertility were observed at exposures that were 21 and 43 times the expected therapeutic level in humans, respectively; nor was there any adverse effect on the development of the pre-implantation embryo or on implantation.
V študijah plodnosti na podganjih samcih in samicah niso opazili nobenih učinkov na število, gibljivost in preživetje spermijev ali na uspešnost parjenja ali plodnost, pri izpostavljenostih, ki so bile 21-krat in 43-krat višje od pričakovane terapevtske ravni pri ljudeh, niti ni bilo nobenega neželenega učinka na razvoj zarodka pred ugnezditvijo ali na ugnezditev samo.
In field studies investigating the effect of treatment and metaphylaxis on mycoplasmosis, all birds (approximately 3 weeks old) received the product when clinical signs were evident in 2 - 5% of the flock.
V terenskih študijah, v katerih so preučevali učinek zdravljenja in metafilakse na mikoplazmozo, so vse ptice (stare približno 3 tedne) prejele zdravilo, ko je 2–5 % jate kazalo klinične znake bolezni.
In final data (adjudicated) from the APC trial in patients treated with celecoxib 800 mg daily for up to 3 years, the excess rates over placebo were 11 events per 1000 patients for myocardial infarction (common); and 5 events per 1000 patients for stroke (uncommon; types of stroke not differentiated).
Po oceni končnih podatkov preskušanj APC in PreSAP pri bolnikih, zdravljenih z 800 mg celekoksiba na dan do 3 leta, je bil presežni delež miokardnih infarktov v primerjavi s placebom 11 dogodkov na 1000 bolnikov (pogosto) in možganskih kapi 5 dogodkov na 1000 bolnikov (občasno; kapi nerazvrščene po tipu).
In FinIP apart from serotypes 6B and 14, culture-confirmed vaccine serotype IPD cases included 7F (1 case in the Synflorix 2+1 clusters), 18C, 19F and 23F (1 case of each in the control clusters).
Vmesna analiza (kohorta po protokolu) je pokazala, da je učinkovitost cepiva proti prvi epizodi CAP z alveolarno konsolidacijo ali plevralnim izlivom (C-CAP, definicija Svetovne zdravstvene organizacije) 25,7 % (95 % IZ: 8,4; 39,6) in proti prvi epizodi klinično sumljivi CAP, napoteni na rentgensko slikanje, 6,7 % (95 % IZ: 0,7; 12,3).
In first-line treatment, docetaxel 75 mg/m2 is given in combination therapy with doxorubicin (50 mg/m2).
Kot zdravljenje prvega izbora se docetaksel 75 mg/m
In five large long­term clinical trials over 2,500 patients have received treatment with Victoza alone or in combination with metformin, a sulfonylurea (with or without metformin) or metformin plus rosiglitazone.
V petih obsežnih in dolgotrajnih kliničnih preskušanjih so več kot 2.500 bolnikov zdravili samo z zdravilom Victoza ali skupaj z metforminom, sulfonilsečnino (z ali brez metformina) ali metforminom in rosiglitazonom.
In five of the studies, the effects of Enviage taken alone were
V petih študijah so učinke jemanja zdravila Enviage,
In five of the studies, the effects of Tekturna taken alone were
V petih študijah so učinke jemanja zdravila
In fluconazole-resistant non albicans species, a successful outcome was seen in3/3C.krusei (complete responses) and 6/8 C. glabrata (5 complete,1 partial response) infections.
Pri ne-albicans vrstah, odpornih na flukonazol, so uspešen odziv ugotovili pri 3/3 okužbah s C. krusei (popolni odzivi) in 6/8 okužbah s C. glabrata (5 popolnih, 1 delni odziv).
In follicular lymphoma, Zydelig is used on its own in patients whose disease has not responded to two previous treatments.
Pri folikularnem limfomu se zdravilo Zydelig uporablja kot samostojno zdravilo pri bolnikih, ki se niso odzvali na dve predhodni zdravljenji.
In four clinical studies with axitinib for the treatment of patients with RCC (N = 537), elevated haemoglobin above ULN was observed in 13.6% receiving axitinib.
V štirih kliničnih študijah z aksitinibom pri zdravljenju bolnikov z RCC (n = 537) so zvišane ravni hemoglobina nad ZMN ugotovili pri 13,6 % bolnikov, ki so prejemali aksitinib.
In four more studies, the effects on the blood sugar levels of the higher strength of Toujeo (300 units/ml) were compared with those of insulin glargine 100 units/ml in 3,045 patients with either type 1 or type 2 diabetes.
V štirih nadaljnjih študijah so učinke višje jakosti zdravila Toujeo (300 enot/ml) na raven sladkorja v krvi primerjali z učinki insulina glargina 100 enot/ml pri 3 045 bolnikih s sladkorno boleznijo tipa 1 ali tipa 2.
In four of these studies, oromucosal midazolam was compared with rectal diazepam and the measure of effectiveness was the treatment’s ability to stop the seizure within 10 minutes.
V štirih od teh študij so oralni midazolam primerjali z rektalnim diazepamom, merilo učinkovitosti pa je bila sposobnost zdravila, da v 10 minutah zaustavi epileptični napad.
In four open label phase 1 and 2 clinical trials patients were treated with at least one dose of Erivedge monotherapy at doses  150 mg.
V štirih odprtih kliničnih preskušanjih faze I in II so bolnike zdravili z vsaj enim odmerkom zdravila Erivedge v monoterapiji z odmerjanjem  150 mg.
In four pivotal clinical trials, 1305 adult patients were treated with Zinforo (600 mg administered over 60 minutes every 12 hours).
V štirih ključnih kliničnih preskušanjih je zdravilo Zinforo (600 mg v obdobju 60 minut na 12 ur) prejemalo 1305 odraslih bolnikov.
In four placebo-controlled studies, treatment with empagliflozin as monotherapy or add-on therapy to metformin, pioglitazone, or metformin plus a sulfonylurea resulted in mean changes from baseline in FPG of -20.5 mg/dl [-1.14 mmol/l] for empagliflozin 10 mg and -23.2 mg/dl [-1.29 mmol/l] for empagliflozin 25 mg compared to placebo (7.4 mg/dl [0.41 mmol/l]).
V štirih s placebom nadzorovanih študijah je zdravljenje z empagliflozinom kot samostojno zdravljenje ali dodatno zdravljenje k metforminu, pioglitazonu ali metforminu s sulfonilsečnino povzročilo povprečno spremembo od izhodiščne vrednosti glede na placebo (7,4 mg/dl [0,41 mmol/l]) za vrednost FPG -20,5 mg/dl [–1,14 mmol/l] za empagliflozin 10 mg in -23,2 mg/dl [–1,29 mmol/l] za empagliflozin 25 mg.
In four separate studies (N = 9 to 12) the mean steady state trough plasma concentration ranged from 2.6 to 3.4 g/ml.
V štirih ločenih študijah (n = 9 do 12) so povprečne plazemske koncentracije v stanju dinamičnega ravnovesja pred naslednjim odmerkom obsegale vrednosti od 2,6 do 3,4 g/ml.
In further field studies, chicks from parent stock with evidence of Mycoplasma gallisepticum infection were administered Aivlosin for the first three days of life followed by a second course at 16 - 19 days of age (a period of management stress).
V nadaljnjih terenskih študijah so piščanci iz starševske jate, pri kateri so ugotovili okužbo z Mycoplasma gallisepticum, prejemali zdravilo Aivlosin prve tri dni življenja, čemur je sledil drugi cikel pri starosti 16–19 dni (obdobje upravljanja stresa).
In further field studies, chicks from parent stock with evidence of Mycoplasma gallisepticum infection were administered the product for the first three days of life followed by a second course at 16 - 19 days of age (a period of management stress).
V nadaljnjih terenskih študijah so piščanci iz starševske jate, pri kateri so ugotovili okužbo z Mycoplasma gallisepticum, prejemali zdravilo Aivlosin prve tri dni življenja, čemur je sledil drugi cikel pri starosti 16–19 dni (obdobje upravljanja stresa).
In future, the immune system will be able to produce antibodies quickly and in large numbers when it is exposed to Japanese encephalitis virus.
Ob ponovni izpostavitvi virusu japonskega encefalitisa v prihodnosti jih bo imunski sistem lahko tvoril hitreje in v večjem številu.
In GEICAM 9805 study, 3 patients (0.6%) in TAC arm and 3 patients (0.6%) in FAC arm developed congestive heart failure during the follow-up period.
V študiji GEICAM 9805 se je 3 bolnicam (0,6 %) v kraku TAC in 3 bolnicam (0,6 %) v kraku FAC med obdobjem spremljanja pojavilo kongestivno srčno popuščanje.
In GEICAM 9805 study, alopecia persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm.
V študiji GEICAM 9805 je alopecija trajala v obdobje spremljanja (mediano obdobje spremljanja 10 let in 5 mesecev); njeno nadaljnjo prisotnost so zabeležili pri 49 bolnicah (9,2 %) v kraku TAC in pri 35 bolnicah (6,7 %) v kraku FAC.
In GEICAM 9805 study, alopecia persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 49 patients (9.2%) in TAC arm and 35 patients (6.7%) in FAC arm.
V študiji GEICAM 9805 je alopecija trajala v obdobje spremljanja (mediano obdobje spremljanja 10 let in 5 mesecev); njeno nadaljnjo prisotnost so zabeležili pri 49 bolnicah (9,2 %) v kraku TAC in pri 35 bolnicah (6,7 %) v kraku FAC.
In GEICAM 9805 study, amenorrhoea persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 18 patients (3.4%) in TAC arm and 5 patients (1.0%) in FAC arm.
V študiji GEICAM 9805 je amenoreja trajala v obdobje spremljanja (mediano obdobje spremljanja 10 let in 5 mesecev); njeno nadaljnjo prisotnost so zabeležili pri 18 bolnicah (3,4 %) v kraku TAC in pri 5 bolnicah (1,0 %) v kraku FAC.
In GEMINI I and II controlled studies, 4% of vedolizumab-treated patients and 3% of placebo-treated patients experienced an adverse event defined by the investigator as infusion-related reaction (IRR) (see section 4.4).
V nadzorovanih študijah GEMINI I in II so o neželenem učinku, ki ga je raziskovalec opredelil kot reakcijo, povezano z infundiranjem, poročali pri 4 % bolnikov, ki so prejemali vedolizumab, in 3 % bolnikov, ki so prejemali placebo (glejte poglavje 4.4).
In GEMINI I and II controlled studies, 5% (3 of 61) of the patients who had an adverse event assessed by the investigator as an IRR were persistently anti-vedolizumab antibody-positive.
V nadzorovanih študijah GEMINI I in II je 5 % (3 od 61) bolnikov, ki so imeli neželeni učinek, ki ga je raziskovalec ocenil kot reakcijo, povezano z infundiranjem, bilo persistentno pozitivnih na protitelesa proti vedolizumabu.
In GEMINI I, two cohorts of patients received vedolizumab at Week 0 and Week 2: cohort 1 patients were randomised to receive either vedolizumab 300 mg or placebo in a double-blind fashion, and cohort 2 patients were treated with open-label vedolizumab 300 mg.
V študiji GEMINI I sta dve kohorti bolnikov prejeli vedolizumab na 0. teden in 2. teden: prva kohorta bolnikov je bila na dvojno slep način randomizirana bodisi na vedolizumab v odmerku 300 mg ali placebo, druga kohorta bolnikov pa se je z vedolizumabom v odmerku 300 mg zdravila na odprt način.
In GEMINI II, approximately half of patients had previously failed TNFα antagonist therapy.
V študiji GEMINI II se približno polovica bolnikov ni odzvala na predhodno zdravljenje z zaviralcem TNFα.
In general adequate follicular development is achieved on average by the tenth day of treatment (range 5 to 20 days).
Na splošno je zadosten folikularni razvoj v povprečju dosežen do desetega dneva zdravljenja (razpon 5 do 20 dni).
In general for immunoglobulin products, adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Na splošno se pri uporabi imunoglobulinskih zdravil občasno pojavijo neželene reakcije, kot so mrazenje, glavobol, zvišana telesna temperatura, bruhanje, alergijske reakcije, navzea, artralgija, nizek krvni tlak in zmerna bolečina v križu.
In general these reactions disappear within 3 weeks post primary vaccination.
Na splošno ta oteklina izgine v 3 tednih po prvem cepljenju.
In general this disappears within 4 days.
Običajno mine v 4 dneh.
In general, administration of alirocumab also resulted in a statistically significant greater percent reduction in total cholesterol (Total-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (Apo B), and lipoprotein (a) [Lp(a)] as compared to placebo/ ezetimibe, whether or not patients were concomitantly being treated with a statin.
Na splošno je uporaba alirokumaba prinesla tudi statistično značilno večje znižanje celokupnega holesterola, holesterola v lipoproteinih, ki niso velike gostote (ne-HDL-H), apolipoproteina B (Apo B) in lipoproteina (a) [Lp(a)] kot placebo/ezetimib, ne glede na to, ali so bolniki sočasno jemali statin ali ne.
In general, adverse reactions were similar to those seen in adults, with the exception of vomiting, rash and pyrexia, which were reported more frequently in children than in adults.
Na splošno so bile neželene reakcije podobne kot pri odraslih, z izjemo bruhanja, izpuščaja in pireksije, o katerih so poročali bolj pogosto pri otrocih kot pri odraslih.
In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
Na splošno je treba pri vseh bolnikih, ki se zdravijo z zdravili, ki vsebujejo koagulacijski faktor VIII, z ustreznim kliničnim opazovanjem in laboratorijskimi preiskavami skrbno spremljati, ali je prišlo do nastanka zaviralcev.
In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
Na splošno je treba vse bolnike, ki se zdravijo z zdravili s koagulacijskim faktorjem VIII, skrbno spremljati glede razvoja inhibitorjev, in sicer z ustreznim kliničnim opazovanjem in laboratorijskimi testi.
In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
Vse bolnike, ki se zdravijo z zdravili s koagulacijskim faktorjem VIII, je treba ustrezno klinično in laboratorijsko skrbno spremljati glede nastanka inhibitorjev.
In general, all patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
V splošnem je treba vse bolnike, zdravljene s faktorjem koagulacije VIII, skrbno spremljati glede nastanka zaviralcev z ustreznim kliničnim opazovanjem in z laboratorijskimi testi.
In general, all patients treated with human coagulation FVIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
Na splošno je treba vse bolnike, zdravljene s humanim koagulacijskim FVIII, skrbno spremljati glede nastanka inhibitorjev z ustreznimi kliničnimi opazovanji in laboratorijskimi preiskavami.
In general, an infusion rate of 0.21 mg/kg/hour should not be exceeded without checking for coagulation abnormalities which might be preventing an appropriate aPTT response.
Na splošno pa hitrost infundiranja ne sme presegati 0,21 mg/kg/h brez predhodnega ugotavljanja morebitnih koagulacijskih nepravilnosti, ki bi lahko preprečevale ustrezen odgovor aPTT.
In general, antifungal therapy should continue for at least 14 days after the last positive culture.
Praviloma je treba antimikotično zdravljenje nadaljevati vsaj še 14 dni po zadnji pozitivni kulturi.
In general, bradycardia responded well to discontinuation of BRINAVESS and/or administration of atropine.
Na splošno so se bolniki, pri katerih se je pojavila bradikardija, dobro odzvali na prenehanje dajanja zdravila BRINAVESS in/ali uporabo atropina.
In general, caution must be exercised when prescribing Sebivo to older patients in view of the greater frequency of decreased renal function due to concomitant disease or concomitant use of other medicinal products.
Na splošno je pri predpisovanju zdravila Sebivo starejšim ljudjem potrebna previdnost, predvsem zaradi večje pogostnosti zmanjšanega delovanja ledvic zaradi spremljajočih bolezni ali sočasne uporabe drugih zdravil.
In general, dual blockade of the RAAS by combining aliskiren with an ACEI or an ARB is not recommended (see paragraph “Dual blockade of the renin-angiotensin-aldosterone system (RAAS)” above and also sections 4.5 and 4.8).
Načeloma dvojno zaviranje sistema renin-angiotenzin-aldosteron s kombinacijo aliskirena in zaviralcev ACE ali antagonistov receptorjev angiotenzina II ni priporočljivo (glejte odstavek »Dvojno zaviranje sistema renin-angiotenzin-aldosteron (RAAS, renin-angiotensin-aldosterone system)« zgoraj in poglavji 4.5 ter 4.8).
In general, elvitegravir pharmacokinetics in paediatric patients (12 to < 18 years of age) and emtricitabine pharmacokinetics in children (aged 4 months to 18 years of age) are similar to those seen in adults.
Na splošno so farmakokinetične lastnosti elvitegravirja pri pediatričnih bolnikih (v starosti od 12 do < 18 let) in emtricitabina pri pri pediatričnih bolnikih (v starosti od 4 mesecev do 18 let) podobne tistim, ki so bile opažene pri odraslih.
In general, emtricitabine pharmacokinetics in HBV infected patients were similar to those in healthy subjects and in HIV infected patients.
Na splošno je bila farmakokinetika emtricitabina pri bolnikih, okuženih z virusom HBV, podobna tisti pri zdravih osebah in bolnikih, okuženih z virusom HIV.
In general, emtricitabine pharmacokinetics in HBV infected patients were similar to those in healthy subjects and in HIV infected patients.
Na splošno so bile farmakokinetične lastnoti emtricitabina pri bolnikih, okuženih z virusom HBV zelo podobne tistim pri zdravih osebah in bolnikih, okuženih z virusom HIV.
In general, emtricitabine pharmacokinetics in HBV infected subjects were similar to those in healthy subjects and in HIV infected subjects.
Na splošno so bile farmakokinetične lastnosti emtricitabina pri osebah, okuženih z virusom HBV zelo podobne tistim pri zdravih osebah in osebah, okuženih z virusom HIV.
In general, expected signs and symptoms are those resulting from an exaggeration of paliperidone’s known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, QT prolongation, and extrapyramidal symptoms.
Na splošno lahko pričakujemo znake in simptome, ki so posledica prekomernih farmakoloških učinkov paliperidona, to so zaspanost in sedacija, tahikardija, hipotenzija, podaljšanje intervala QT in ekstrapiramidni simptomi.